Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 650.51
TGTX's Cash-to-Debt is ranked higher than
55% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. TGTX: 650.51 )
Ranked among companies with meaningful Cash-to-Debt only.
TGTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 5325.25 Max: No Debt
Current: 650.51
Equity-to-Asset 0.66
TGTX's Equity-to-Asset is ranked higher than
52% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. TGTX: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
TGTX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.83 Max: 0.96
Current: 0.66
0.16
0.96
Piotroski F-Score: 3
Altman Z-Score: 10.91
Beneish M-Score: -5.36
WACC vs ROIC
24.00%
-586.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -51952.63
TGTX's Operating Margin % is ranked lower than
99% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. TGTX: -51952.63 )
Ranked among companies with meaningful Operating Margin % only.
TGTX' s Operating Margin % Range Over the Past 10 Years
Min: -141552.63  Med: -41565.79 Max: -15109.21
Current: -51952.63
-141552.63
-15109.21
Net Margin % -51482.24
TGTX's Net Margin % is ranked lower than
99% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. TGTX: -51482.24 )
Ranked among companies with meaningful Net Margin % only.
TGTX' s Net Margin % Range Over the Past 10 Years
Min: -95121.05  Med: -41413.82 Max: -13472.37
Current: -51482.24
-95121.05
-13472.37
ROE % -107.98
TGTX's ROE % is ranked lower than
79% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. TGTX: -107.98 )
Ranked among companies with meaningful ROE % only.
TGTX' s ROE % Range Over the Past 10 Years
Min: -3919.22  Med: -92.85 Max: -40.04
Current: -107.98
-3919.22
-40.04
ROA % -89.17
TGTX's ROA % is ranked lower than
81% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. TGTX: -89.17 )
Ranked among companies with meaningful ROA % only.
TGTX' s ROA % Range Over the Past 10 Years
Min: -543.33  Med: -87.87 Max: 6.57
Current: -89.17
-543.33
6.57
ROC (Joel Greenblatt) % -6856.05
TGTX's ROC (Joel Greenblatt) % is ranked lower than
83% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. TGTX: -6856.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TGTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -58800  Med: -17586.18 Max: -6856.05
Current: -6856.05
-58800
-6856.05
3-Year Revenue Growth Rate -20.60
TGTX's 3-Year Revenue Growth Rate is ranked lower than
74% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. TGTX: -20.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TGTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: -20.6
0
44.2
3-Year EBITDA Growth Rate 28.00
TGTX's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. TGTX: 28.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TGTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -48.5 Max: 73
Current: 28
0
73
3-Year EPS without NRI Growth Rate 25.50
TGTX's 3-Year EPS without NRI Growth Rate is ranked higher than
79% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. TGTX: 25.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TGTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -37 Max: 76.5
Current: 25.5
0
76.5
GuruFocus has detected 4 Warning Signs with TG Therapeutics Inc $TGTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TGTX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

TGTX Guru Trades in

Q2 2015

TGTX Guru Trades in Q2 2015

Jim Simons Sold Out
» More
Q2 2016

TGTX Guru Trades in Q2 2016

Paul Tudor Jones 23,516 sh (New)
» More
Q3 2016

TGTX Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TGTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BCRX, NAS:ANIP, NAS:BSTC, AMEX:BTX, NAS:CASC, NAS:BDSI, NAS:BMRN » details
Traded in other countries:NKB2.Germany,
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of medically important pharmaceutical products for the treatment of cancer & other underserved therapeutic needs.

TG Therapeutics Inc, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on the acquisition, development, and commercialization of new and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 or ublituximab which is a novel, third generation monoclonal antibody that targets a specific and single epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases or PI3Ks are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K: alpha, beta, delta, and gamma, of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers. The Company competes with Roche Group, Gazyva, Spectrum Pharmaceutical, Dr. Reddy's Laboratories', among others.

Ratios

vs
industry
vs
history
PB Ratio 17.77
TGTX's PB Ratio is ranked lower than
92% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. TGTX: 17.77 )
Ranked among companies with meaningful PB Ratio only.
TGTX' s PB Ratio Range Over the Past 10 Years
Min: 2.51  Med: 6.23 Max: 20.69
Current: 17.77
2.51
20.69
PS Ratio 2912.50
TGTX's PS Ratio is ranked lower than
99% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. TGTX: 2912.50 )
Ranked among companies with meaningful PS Ratio only.
TGTX' s PS Ratio Range Over the Past 10 Years
Min: 558.33  Med: 2025 Max: 4670
Current: 2912.5
558.33
4670
Current Ratio 3.01
TGTX's Current Ratio is ranked lower than
61% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. TGTX: 3.01 )
Ranked among companies with meaningful Current Ratio only.
TGTX' s Current Ratio Range Over the Past 10 Years
Min: 0.1  Med: 5.35 Max: 21.25
Current: 3.01
0.1
21.25
Quick Ratio 3.01
TGTX's Quick Ratio is ranked lower than
58% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. TGTX: 3.01 )
Ranked among companies with meaningful Quick Ratio only.
TGTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 5.35 Max: 21.25
Current: 3.01
0.1
21.25
Days Sales Outstanding 201.71
TGTX's Days Sales Outstanding is ranked lower than
90% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. TGTX: 201.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
TGTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.84  Med: 204.11 Max: 446.64
Current: 201.71
64.84
446.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.90
TGTX's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. TGTX: -16.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TGTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -851.2  Med: -26 Max: 0
Current: -16.9
-851.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 24.79
TGTX's Price-to-Net-Cash is ranked lower than
84% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. TGTX: 24.79 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TGTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.19  Med: 7.1 Max: 39.88
Current: 24.79
1.19
39.88
Price-to-Net-Current-Asset-Value 20.09
TGTX's Price-to-Net-Current-Asset-Value is ranked lower than
86% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. TGTX: 20.09 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TGTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.18  Med: 7.04 Max: 32.06
Current: 20.09
1.18
32.06
Price-to-Tangible-Book 18.20
TGTX's Price-to-Tangible-Book is ranked lower than
89% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. TGTX: 18.20 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TGTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.65  Med: 6.45 Max: 28.78
Current: 18.2
0.65
28.78
Price-to-Median-PS-Value 1.44
TGTX's Price-to-Median-PS-Value is ranked lower than
70% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. TGTX: 1.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TGTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 1.47 Max: 1.96
Current: 1.44
0.32
1.96
Earnings Yield (Greenblatt) % -12.59
TGTX's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. TGTX: -12.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TGTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3772.5  Med: 194.4 Max: 1470.1
Current: -12.59
-3772.5
1470.1

More Statistics

Revenue (TTM) (Mil) $0.15
EPS (TTM) $ -1.60
Beta2.86
Short Percentage of Float28.81%
52-Week Range $4.10 - 15.05
Shares Outstanding (Mil)57.73

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 0 7
EPS ($) -1.61 -1.86
EPS without NRI ($) -1.61 -1.86
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TGTX

Headlines

Articles On GuruFocus.com
TG Therapeutics Surges 85% on Results From Study Mar 06 2017 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 

More From Other Websites
ETFs with exposure to TG Therapeutics, Inc. : March 27, 2017 Mar 27 2017
TG THERAPEUTICS, INC. Financials Mar 22 2017
TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 Mar 22 2017
TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for... Mar 20 2017
TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference Mar 17 2017
TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention Mar 16 2017
TG THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 16 2017
TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference Mar 13 2017
TG Therapeutics reports 4Q loss Mar 10 2017
TG Therapeutics reports 4Q loss Mar 10 2017
Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps Mar 10 2017
TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events Mar 10 2017
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business... Mar 10 2017
Q4 2016 TG Therapeutics Inc Earnings Release - After Market Close Mar 10 2017
TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Mar 09 2017
TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2016 Financial Results... Mar 09 2017
TG Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock Mar 09 2017
TG Therapeutics Announces Proposed Public Offering of Common Stock Mar 08 2017
Harry Boxer’s six biotechnology stocks to watch Mar 07 2017
Here’s What’s Next For TG Therapeutics Inc (TGTX) Mar 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)